GlassScriptPhysician profile
Michael P Gallagher
NPI 1386855088
$1,184.34
in general payments reported to CMS, 2019-2025
25 companies · $436 in 2025
The $436 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.20 · 2020: $153 · 2021: $139 · 2022: $192 · 2023: $39.63 · 2024: $169 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $200.82 | 2020-2022 | |
| Boston Scientific Corporation | $169.49 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $135.20 | 2025 | Entyvio |
| Madrigal Pharmaceuticals | $122.13 | 2025 | Rezdiffra |
| Vanda Pharmaceuticals INC. | $120.17 | 2020-2021 | |
| Ardelyx, INC. | $46.03 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $35.97 | 2025 | Zenpep |
| Neurelis, INC. | $31.43 | 2020-2021 | |
| Phadia US INC. | $25.37 | 2025 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $25.10 | 2022 | |
| Sk Life Science, INC. | $23.77 | 2022 | |
| Merz Pharmaceuticals, LLC | $23.59 | 2025 | Xeomin |
| Avanir Pharmaceuticals, INC. | $23.40 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.69 | 2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $21.06 | 2023 | Ztlido |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Normatec Industries, LP | $20.42 | 2019 | |
| Grt US Holding, INC. | $18.83 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.57 | 2023 | |
| Janssen Biotech, INC. | $17.24 | 2025 | Tremfya, Stelara |
| Cardinal Health 200 LLC | $15.93 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.27 | 2022 | |
| Tonix Medicines, INC. | $14.62 | 2025 | Zembrace Symtouch |
| Neurocrine Biosciences, INC. | $13.54 | 2022 | |
| Phathom Pharmaceuticals, INC. | $12.05 | 2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.